Ta strona została przetłumaczona automatycznie i dokładność tłumaczenia nie jest gwarantowana. Proszę odnieść się do angielska wersja za tekst źródłowy.

Evaluation of Calcified Coronary Lesion Preparation With the Naviscore Scoring Balloon (MILOU)

10 czerwca 2026 zaktualizowane przez: Stephane Carlier, University of Mons

MILOU: Minimize Intra Luminal Obstructive Underexpansion: A Prospective, Multi-Center Randomized Trial for the Evaluation of Calcified Coronary Lesion Preparation With the Naviscore Scoring Balloon

The purpose of this clinical study is to evaluate the effectiveness and safety of a specialized medical device, the Naviscore scoring balloon, in preparing calcified coronary artery narrowings before the implantation of a drug-eluting stent. During percutaneous coronary interventions, the presence of calcified plaques in the heart arteries represents a major challenge because it can prevent stents from expanding fully. When a stent remains under-expanded, it significantly increases the long-term risk of arterial re-narrowing or blood clot formation. To optimize stent expansion, appropriate preparation of the diseased vessel section before stent insertion is a critical phase.

This study is a prospective, multi-center randomized trial designed to test the hypothesis that treating calcified coronary lesions with the Naviscore scoring balloon will achieve a better stent expansion and a larger final minimal stent area compared to standard lesion preparation using regular non-compliant balloons. Eligible participants will be randomized in a one-to-one ratio to one of these two lesion preparation strategies. For all included patients, standard drug-eluting stents will be deployed. The study will use intravascular ultrasound imaging to evaluate the final minimum area of the stent directly inside the treated artery at the site of the highest initial calcium burden. Participant health and clinical outcomes will be monitored for up to twelve months following the procedure.

Przegląd badań

Status

Jeszcze nie rekrutacja

Warunki

Interwencja / Leczenie

Szczegółowy opis

Percutaneous transluminal coronary angioplasty (PTCA) is the main technique in percutaneous coronary intervention (PCI). It aims to restore coronary blood flow by mechanically enlarging a stenotic arterial segment through controlled balloon inflation within the vessel lumen. The acute luminal gain with balloon angioplasty is the result of multiple mechanisms, ranging from percolation and longitudinal redistribution of atheroma, to plaque fracture, and overstretching of the vessel wall, often accompanied by intimal tearing and medial dissection. While contemporary drug-eluting technologies have significantly improved long-term clinical outcomes, fibrocalcified atheromatous intracoronary plaques still present a significant challenge for stent crossing and optimal deployment.

Research has demonstrated that suboptimal stent expansion and malapposition are significant contributing factors to restenosis and stent thrombosis rates, regardless of the type of stent used. Intravascular imaging registries have identified that twenty to thirty percent of deployed stents remain under-expanded or malapposed in daily clinical practice. Severe coronary calcification can make it difficult to deliver devices and can limit the expansion of stents, which can result in suboptimal improvement in blood flow and an increased risk of adverse events, including target lesion failure. Furthermore, heavily calcified lesions have been found to be associated with higher rates of vessel dissection, perforation and impaired anti-proliferative drug delivery, resulting from the mechanical barrier of the calcium burden.

In order to achieve successful stent deployment, optimal preparation of fibro-calcific lesions is essential and involves a number of plaque modification strategies. Focused force angioplasty is a procedure that targets specific locations of the plaque, focusing inflation forces on the area to induce localized stress and facilitate cracking. It is crucial to ensure that the pre-dilatation balloon is correctly sized to maximise safety by minimising the risk of advanced coronary perforation or severe medial damage. It is imperative that sizing compliance chart data is followed rigorously, as compliant balloons can display an unpredictable non-linear expansion behaviour at higher pressures, whereas non-compliant balloons maintain a stable volume, concentrating their dilating force directly at the calcified site up to their rated burst pressure. Semi-compliant pre-dilatation balloons often expand asymmetrically in resistant lesions, increasing the risk of edge dissections. The sizing and performance of scoring devices and non-compliant balloons remains limited in contemporary clinical literature. This randomised trial is designed to evaluate the post-market clinical performance, safety and comparative effectiveness of the Naviscore scoring balloon catheter manufactured by iVascular.

Typ studiów

Interwencyjne

Zapisy (Szacowany)

200

Faza

  • Nie dotyczy

Kontakty i lokalizacje

Ta sekcja zawiera dane kontaktowe osób prowadzących badanie oraz informacje o tym, gdzie badanie jest przeprowadzane.

Kontakt w sprawie studiów

Lokalizacje studiów

  • Belgia
      • Bonheiden, Belgia, 2820
        • Imelda
      • Brussels, Belgia, 1070
        • Hôpital Erasme - Cliniques universitaires de Bruxelles
        • Kontakt:
        • Główny śledczy:
          • Gabriela Flores Vivian, MD
      • Libramont, Belgia, 6800
        • Hôpital Vivalia
        • Kontakt:
        • Główny śledczy:
          • Chadi Ghafari, MD, PhD
      • Liège, Belgia, 4000
      • Lodelinsart, Belgia, 6042
        • Humani CHU Charleroi - Chimay
        • Kontakt:
        • Główny śledczy:
          • Mohamed Ben Yedder, MD
    • Hainaut
      • Mons, Hainaut, Belgia, 7000
        • CHU - HELORA site Kennedy
        • Kontakt:
        • Główny śledczy:
          • Stéphane Carlier, MD, Phd
  • Hiszpania
      • Barcelona, Hiszpania, 08025
        • Hospital de Sant Pau
        • Kontakt:
        • Kontakt:
          • Elena Jiménez Xarrié
          • Numer telefonu: +34628839525
        • Główny śledczy:
          • Estefanía Fernández-Peregrina, MD
      • Barcelona, Hiszpania, 08901-08908
      • Cadiz, Hiszpania, 11009
        • Hospital Puerta del Mar
        • Kontakt:
        • Główny śledczy:
          • Alejandro Gutiérrez-Barrios, MD
      • Cáceres, Hiszpania, 10003
        • Hospital San Pedro De Alcantara
        • Kontakt:
        • Główny śledczy:
          • Juan Carlos Rama, MD
      • Valencia, Hiszpania, 46026
        • Hospital La Fe
        • Kontakt:
        • Kontakt:
        • Główny śledczy:
          • Jorge Sanz Sanchez, MD
      • Valladolid, Hiszpania, 47003
        • Hospital Clínico Universitario de Valladolid
        • Główny śledczy:
          • Ignacio J Amat Santos, MD
        • Kontakt:
          • Ignacio J Amat Santos, MD
          • Numer telefonu: 86571 +34983420000
          • E-mail: ijamat@gmail.com
        • Kontakt:
  • Luksemburg
      • Luxembourg, Luksemburg, 1210
        • INCCI Haerz Zenter
        • Kontakt:
        • Główny śledczy:
          • Bruno Pereira, MD
  • Portugalia
      • Vila Nova de Gaia, Portugalia, 4430-999
        • Centro Hospitalar de Vila Nova de Gaia/Espinho
        • Kontakt:
        • Główny śledczy:
          • Alberto Rodrigues, MD

Kryteria uczestnictwa

Badacze szukają osób, które pasują do określonego opisu, zwanego kryteriami kwalifikacyjnymi. Niektóre przykłady tych kryteriów to ogólny stan zdrowia danej osoby lub wcześniejsze leczenie.

Kryteria kwalifikacji

Wiek uprawniający do nauki

  • Dorosły
  • Starszy dorosły

Akceptuje zdrowych ochotników

Nie

Opis

Inclusion Criteria:

  • Patient written consent is given, ≥18 years.
  • A de novo lesion to be treated in a vessel between 2.5 and 4.0 mm.
  • Moderate to heavily calcified lesions detected by coronary angiography on two orthogonal views, and confirmed by IVUS if the lesion can be crossed with the catheter.

Exclusion Criteria:

  • Patient <18 years old.
  • Pregnant female.
  • Contraindication to dual antiplatelet therapy.
  • Thrombocytopenia (under 100 000).
  • Major surgical intervention planned within one year.
  • Significant left main lesion.
  • Chronic total occlusion.
  • Lesion in a graft.
  • In-stent restenosis lesion.
  • Lesion responsible of a ST elevated Myocardial Infarction (STEMI)

Plan studiów

Ta sekcja zawiera szczegółowe informacje na temat planu badania, w tym sposób zaprojektowania badania i jego pomiary.

Jak projektuje się badanie?

Szczegóły projektu

  • Główny cel: Leczenie
  • Przydział: Randomizowane
  • Model interwencyjny: Przydział równoległy
  • Maskowanie: Brak (otwarta etykieta)

Broń i interwencje

Grupa uczestników / Arm
Interwencja / Leczenie
Aktywny komparator: Standard NC group
Lesion preparation of calcified coronary stenosis performed using standard non-compliant (NC) balloons. Balloons are sized according to a 0.8:1 to 1:1 ratio relative to the reference lumen and inflated below the rated burst pressure. To maintain a strict comparison and eliminate any scoring effect, no parallel guidewire is allowed in the target vessel during inflation.
Urządzenie: Non-Compliant (NC) Angioplasty Balloon
Conventional non-compliant (NC) PTCA balloon catheter used for standard lesion pre-dilatation according to routine clinical practice, inflated below the rated burst pressure without parallel guidewires in place.
Inne nazwy:
  • Conventional PTCA Balloon
Eksperymentalny: Naviscore group
Lesion preparation of calcified coronary stenosis performed using the Naviscore scoring balloon catheter before drug-eluting stent implantation. The device is sized according to a 0.8:1 to 1:1 ratio relative to the reference lumen. To maximize the plaque-modification effect of the external nitinol wires, a mandatory mechanical mobilization sequence must be performed: the balloon is inflated to nominal pressure, fully deflated, mobilized within the lesion, and reinflated. This specific sequence must be repeated 3 to 4 times across the target segment.
Urządzenie: Scoring Balloon PTCA Catheter
Percutaneous coronary preparation of calcified coronary stenosis using the rapid exchange Naviscore scoring balloon catheter before drug-eluting stent deployment. The device incorporates an over-the-balloon metallic nitinol element designed to focally concentrate dilation forces, minimizing balloon slippage and scoring the atheromatous plaque at lower pressures to facilitate optimal stent expansion. Sizing is based on a 0.8:1 to 1:1 ratio relative to the reference lumen. Operators must execute a specific sequence of inflating the scoring balloon to nominal pressure, fully deflating it, mobilizing it within the lesion, and reinflating it, repeated three to four times across the target segment to ensure multi-focal plaque disruption before stenting.
Inne nazwy:
  • Naviscore Scoring Balloon

Co mierzy badanie?

Podstawowe miary wyniku

Miara wyniku
Opis środka
Ramy czasowe
Final Minimal Stent Area (MSA)
Ramy czasowe: Immediately post-stenting optimization during the index percutaneous coronary intervention (PCI) procedure.
The minimal stent area (MSA) will be measured in square millimeters by intravascular ultrasound (IVUS) after final procedural optimization. The primary comparison will evaluate the MSA specifically at the exact site of the initial heaviest calcium burden to demonstrate the superiority of the Naviscore scoring balloon over standard non-compliant (NC) balloons.
Immediately post-stenting optimization during the index percutaneous coronary intervention (PCI) procedure.

Miary wyników drugorzędnych

Miara wyniku
Opis środka
Ramy czasowe
Minimal Stent Area (MSA) Across the Entire Stented Segment
Ramy czasowe: Immediately post-stenting optimization during the index percutaneous coronary intervention (PCI) procedure
The minimal stent area (MSA) in square millimeters measured across the entire length of the deployed segment using intravascular ultrasound (IVUS) pullbacks to evaluate overall stent expansion expansion
Immediately post-stenting optimization during the index percutaneous coronary intervention (PCI) procedure
Stent Eccentricity at the Site of the Minimal Stent Area
Ramy czasowe: Immediately post-stenting optimization during the index percutaneous coronary intervention (PCI) procedure
Stent eccentricity index calculated as the ratio of the minimum stent diameter over the maximum stent diameter, measured via intravascular ultrasound (IVUS) at the exact cross-section of the minimal stent area segment
Immediately post-stenting optimization during the index percutaneous coronary intervention (PCI) procedure
Stent Eccentricity at the Initial Heaviest Calcium Burden Site
Ramy czasowe: Immediately post-stenting optimization during the index percutaneous coronary intervention (PCI) procedure
Stent eccentricity index calculated as the ratio of the minimum stent diameter over the maximum stent diameter, measured via intravascular ultrasound (IVUS) specifically at the cross-section matching the initial heaviest baseline calcium plaque burden
Immediately post-stenting optimization during the index percutaneous coronary intervention (PCI) procedure
Device Success Rate
Ramy czasowe: During the index percutaneous coronary intervention (PCI) procedure
Percentage of cases achieving successful delivery of the assigned pre-dilatation balloon, complete inflation with adequate lesion preparation, and the absolute absence of vessel rupture or advanced coronary perforation categorized by the Ellis classification
During the index percutaneous coronary intervention (PCI) procedure
Major Adverse Cardiac Events (MACE) Rate
Ramy czasowe: At 1 and 12 months post-procedure
Percentage of participants experiencing Major Adverse Cardiac Events (MACE), defined as a composite clinical endpoint of myocardial infarction, stroke or transient ischemic attack, or cardiac death
At 1 and 12 months post-procedure
Target Lesion Failure (TLF)
Ramy czasowe: At 1 and 12 months post-procedure
Percentage of participants experiencing Target Lesion Failure (TLF), defined as a composite of cardiac death, target-vessel myocardial infarction defined according to ARC-2 criteria, or clinically indicated Target Lesion Revascularization
At 1 and 12 months post-procedure
Target Vessel Failure (TVF)
Ramy czasowe: At 1 and 12 months post-procedure
Defined as a composite of cardiac death, target-vessel myocardial infarction, or clinically indicated Target Vessel Revascularization (TVR).
At 1 and 12 months post-procedure
Clinically Indicated Target Lesion Revascularization (TLR)
Ramy czasowe: At 1 and 12 months post-procedure
Percentage of participants requiring a repeat percutaneous coronary intervention (PCI) or coronary artery bypass graft surgery (CABG) driven by a recurrent narrowing inside the originally treated target lesion segment (including the stent and its five-millimeter proximal and distal borders), which is accompanied by clinical symptoms of ischemia or objective functional evidence of myocardial ischemia.
At 1 and 12 months post-procedure
Clinically Indicated Target Vessel Revascularization (TVR)
Ramy czasowe: At 1 and 12 months post-procedure
Percentage of participants requiring any repeat percutaneous coronary intervention (PCI) or coronary artery bypass graft surgery (CABG) in any segment of the originally treated target vessel, driven by angiographic restenosis or disease progression, and accompanied by clinical symptoms of ischemia or objective functional evidence of myocardial ischemia.
At 1 and 12 months post-procedure
Procedural Success Rate
Ramy czasowe: During the index percutaneous coronary intervention (PCI) procedure and until hospital discharge (up to 24 hours post-procedure).
Percentage of cases achieving Device Success (successful delivery of the assigned balloon and complete inflation with adequate lesion preparation) combined with a final residual stenosis of less than thirty percent as measured by quantitative coronary angiography (QCA) and a final Thrombolysis in Myocardial Infarction (TIMI) grade 3 flow, without the occurrence of in-hospital Major Adverse Cardiac Events (MACE).
During the index percutaneous coronary intervention (PCI) procedure and until hospital discharge (up to 24 hours post-procedure).
Final Residual Stent Underexpansion
Ramy czasowe: At the end of the index percutaneous coronary intervention (PCI) procedure (immediate post-stenting optimization).
Evaluation of the final residual underexpansion of the drug-eluting stent after deployment and high-pressure post-dilatation, measured in millimeters using motion-corrected X-ray stent visualization software (StentBoost or equivalent stent enhancement method) in two orthogonal views without contrast.
At the end of the index percutaneous coronary intervention (PCI) procedure (immediate post-stenting optimization).
Final Stent Diameter Stenosis
Ramy czasowe: At the end of the index percutaneous coronary intervention (PCI) procedure.
The final percentage of stent diameter stenosis evaluated by quantitative coronary angiography (QCA) at the index procedure after final stent deployment and post-dilatation optimization.
At the end of the index percutaneous coronary intervention (PCI) procedure.
Rate of Procedural Complications
Ramy czasowe: During the index percutaneous coronary intervention (PCI) procedure (immediate intra-procedural period).
The cumulative rate of procedure-related complications during the index procedure, defined as a composite of cardiac death, acute myocardial infarction, emergency coronary artery bypass graft surgery (CABG), coronary artery perforation (Ellis classification), and cardiac tamponade directly related to the use of the Naviscore scoring balloon or the regular non-compliant (NC) balloon.
During the index percutaneous coronary intervention (PCI) procedure (immediate intra-procedural period).
Procedural Cost-Effectiveness
Ramy czasowe: During the index percutaneous coronary intervention (PCI) procedure.
Evaluation of the procedural cost-effectiveness of using the Naviscore scoring balloon compared to standard non-compliant (NC) balloons for calcified lesion preparation, calculated by factoring device costs, overall material utilisation during the intervention, procedure duration, and the need for bailout additional plaque-modification tools or complementary high-pressure devices.
During the index percutaneous coronary intervention (PCI) procedure.

Współpracownicy i badacze

Tutaj znajdziesz osoby i organizacje zaangażowane w to badanie.

Sponsor

University of Mons

Współpracownicy

iVascular S.L.U.

Śledczy

  • Główny śledczy: Stéphane Carlier, MD, PhD, University of Mons
  • Główny śledczy: Antonio Serra

Publikacje i pomocne linki

Osoba odpowiedzialna za wprowadzenie informacji o badaniu dobrowolnie udostępnia te publikacje. Mogą one dotyczyć wszystkiego, co jest związane z badaniem.

Publikacje ogólne

Daty zapisu na studia

Daty te śledzą postęp w przesyłaniu rekordów badań i podsumowań wyników do ClinicalTrials.gov. Zapisy badań i zgłoszone wyniki są przeglądane przez National Library of Medicine (NLM), aby upewnić się, że spełniają określone standardy kontroli jakości, zanim zostaną opublikowane na publicznej stronie internetowej.

Główne daty studiów

Rozpoczęcie studiów (Szacowany)

1 lipca 2026

Zakończenie podstawowe (Szacowany)

1 czerwca 2027

Ukończenie studiów (Szacowany)

1 czerwca 2028

Daty rejestracji na studia

Pierwszy przesłany

10 czerwca 2026

Pierwszy przesłany, który spełnia kryteria kontroli jakości

10 czerwca 2026

Pierwszy wysłany (Rzeczywisty)

16 czerwca 2026

Aktualizacje rekordów badań

Ostatnia wysłana aktualizacja (Rzeczywisty)

16 czerwca 2026

Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości

10 czerwca 2026

Ostatnia weryfikacja

1 czerwca 2026

Więcej informacji

Terminy związane z tym badaniem

Słowa kluczowe

Dodatkowe istotne warunki MeSH

Inne numery identyfikacyjne badania

  • 009 (Nahrain Medical Research Collective (NMRC))
  • Unrestricted grant (Inny numer grantu/finansowania: iVascular)

Plan dla danych uczestnika indywidualnego (IPD)

Planujesz udostępniać dane poszczególnych uczestników (IPD)?

TAK

Opis planu IPD

The individual participant data (IPD) that underlie the results reported in this publication, including the final minimal stent area (MSA) measurements, procedural success data, and relevant clinical adverse event records, will be shared. Supporting documents, including the study protocol, statistical analysis plan, and informed consent forms, will be provided to support the interpretation of the IPD. All data shared will be de-identified to maintain participant confidentiality in accordance with GDPR requirements.

Ramy czasowe udostępniania IPD

Beginning 6 months after the publication of the study results and ending 5 years following the publication date.

Kryteria dostępu do udostępniania IPD

Access is granted to researchers who provide a methodologically sound proposal for secondary analysis. Proposals must be submitted to the Principal Investigators at the University of Mons (UMONS), Belgium. The study's Steering Committee will review each request. Upon approval, data will be shared under a signed data sharing agreement ensuring strict adherence to participant privacy and institutional ethical guidelines.

Typ informacji pomocniczych dotyczących udostępniania IPD

  • PROTOKÓŁ BADANIA
  • SOK ROŚLINNY
  • ICF

Informacje o lekach i urządzeniach, dokumenty badawcze

Bada produkt leczniczy regulowany przez amerykańską FDA

Nie

Bada produkt urządzenia regulowany przez amerykańską FDA

Nie

Te informacje zostały pobrane bezpośrednio ze strony internetowej clinicaltrials.gov bez żadnych zmian. Jeśli chcesz zmienić, usunąć lub zaktualizować dane swojego badania, skontaktuj się z register@clinicaltrials.gov. Gdy tylko zmiana zostanie wprowadzona na stronie clinicaltrials.gov, zostanie ona automatycznie zaktualizowana również na naszej stronie internetowej .

Subskrybuj